Therefore, one of the strongest points of this study is that CMT2F- and dHMN2B-specific in vitro cellular models can be applied for the screening of putative therapeutic molecules, such as HDAC6 inhibitors on peripheral neuropathy. The gene discussed is HSPB1; the disease is peripheral neuropathy.